3/26/2023 | SP | New Issue: UBS prices $100,000 buffered return optimization securities linked to Vertex
|
10/25/2022 | SP | New Issue: RBC sells $190,000 thematic opportunity notes on 16 Top 30 Global Ideas stocks
|
8/18/2022 | SP | New Issue: GS Finance prices $500,000 callable contingent coupon equity notes on Vertex
|
7/5/2022 | BK | Vertex Pharmaceuticals enters $500 million five-year senior revolver
|
4/29/2022 | SP | New Issue: GS Finance sells $9.25 million basket-linked notes tied to 77 stocks
|
3/7/2022 | SP | New Issue: UBS prices $1.25 million trigger phoenix autocallables linked to Vertex
|
8/26/2021 | SP | New Issue: GS Finance prices $13.14 million leveraged basket-linked notes on 179 stocks
|
8/26/2021 | SP | New Issue: TD Bank prices $675,000 callable contingent interest barrier notes on Vertex
|
8/23/2021 | SP | New Issue: JPMorgan sells $630,000 autocallable contingent interest notes on three stocks
|
1/4/2021 | SP | New Issue: UBS prices $2.15 million trigger autocallable contingent yield notes on Vertex
|
12/29/2020 | SP | New Issue: GS Finance sells $1.71 million leveraged basket-linked notes on 23 stocks
|
12/19/2020 | SP | New Issue: Credit Suisse prices $2.8 million Accelerated Return Equity Securities on stock basket
|
12/19/2020 | SP | New Issue: Credit Suisse prices $1.43 million Accelerated Return Equity Securities on stock basket
|
12/18/2020 | SP | New Issue: TD Bank prices $10 million contingent interest buffer autocallables linked to Vertex
|
9/21/2020 | BK | Vertex Pharmaceuticals enters into $2 billion two-year revolver
|
11/13/2019 | SP | New Issue: GS Finance prices $1.13 million contingent coupon autocallables linked to three stocks
|
11/13/2019 | SP | New Issue: GS Finance prices $1.94 million contingent coupon autocallables linked to three stocks
|
11/1/2019 | SP | GS Finance to price contingent coupon notes linked to three stocks
|
11/1/2019 | SP | GS Finance plans contingent coupon autocallables tied to three stocks
|
9/17/2019 | BK | Vertex Pharmaceuticals enters into $500 million five-year revolver
|
10/31/2018 | SP | New Issue: BMO sells $292,000 notes on eight Raymond James biotechnology top picks
|
10/31/2018 | SP | New Issue: BMO sells $390,000 notes on eight Raymond James biotechnology top picks
|
10/11/2018 | SP | BMO plans notes due 2020 tied to Raymond James biotech top picks
|
10/11/2018 | SP | BMO to price notes due 2020 tied to Raymond James biotech top picks
|
10/8/2018 | SP | New Issue: BMO sells $1.23 million notes on eight Raymond James Biotechnology Sector top picks
|
10/8/2018 | SP | New Issue: BMO sells $1.02 million notes on eight Raymond James Biotechnology Sector top picks
|
4/3/2018 | SP | New Issue: JPMorgan sells $2.05 million 19.75% contingent interest autocalls tied to three stocks
|
4/3/2018 | SP | New Issue: JPMorgan sells $1.68 million 18% contingent interest autocalls tied to three stocks
|
4/2/2018 | SP | New Issue: CIBC sells $495,000 notes on eight Raymond James top pick healthcare stocks
|
4/2/2018 | SP | New Issue: CIBC sells $285,000 Raymond James Healthcare Top Selections notes on 16 stocks
|
4/2/2018 | SP | New Issue: CIBC sells $548,000 notes on eight Raymond James top pick healthcare stocks
|
3/26/2018 | SP | New Issue: Barclays prices $864,000 phoenix autocalls tied to Facebook, Vertex, Citi
|
3/21/2018 | SP | Barclays to price phoenix autocallables tied to Facebook, Vertex, Citi
|
3/20/2018 | SP | CIBC plans notes on eight Raymond James top pick healthcare stocks
|
3/20/2018 | SP | CIBC to price notes on eight Raymond James top pick healthcare stocks
|
3/20/2018 | SP | CIBC plans Raymond James Healthcare Top Selections notes on 16 stocks
|
3/20/2018 | SP | CIBC to price notes on 16 Raymond James top pick healthcare stocks
|
3/15/2018 | SP | JPMorgan plans 18% contingent interest autocallables on three stocks
|
2/20/2018 | SP | New Issue: Credit Suisse sells $95,023 call warrants linked to 20 stocks
|
2/16/2018 | SP | New Issue: Credit Suisse sells $149,992 call warrants linked to 20 stocks
|
2/16/2018 | SP | New Issue: Credit Suisse sells $83,500 call warrants linked to 20 stocks
|
2/15/2018 | SP | New Issue: Credit Suisse sells $149,951 call warrants linked to 20 stocks
|
2/15/2018 | SP | New Issue: Credit Suisse sells $175,000 return notes on basket of 20 stocks
|
2/8/2018 | SP | Credit Suisse to price 54-week call warrants linked to 20 stocks
|
2/8/2018 | SP | Credit Suisse to price return notes linked to basket of 20 stocks
|
2/5/2018 | SP | New Issue: JPMorgan sells $5.81 million return notes linked to basket of 20 stocks
|
2/5/2018 | SP | New Issue: Credit Suisse prices $425,971 call warrants linked to 20 stocks
|
1/31/2018 | SP | Credit Suisse to price return notes linked to basket of 20 stocks
|
1/24/2018 | SP | JPMorgan to price return notes linked to basket of 20 stocks
|
1/24/2018 | SP | Credit Suisse to price 54-week call warrants linked to 20 stocks
|
1/24/2018 | SP | New Issue: Credit Suisse prices $639,916 call warrants linked to 20 stocks
|
1/23/2018 | SP | New Issue: Credit Suisse prices $2.79 million return notes on basket of 20 stocks
|
1/18/2018 | SP | Credit Suisse to price return notes linked to basket of 20 stocks
|
11/15/2017 | SP | New Issue: Credit Suisse prices $1.27 million contingent coupon autocallables on three stocks
|
11/15/2017 | SP | New Issue: Credit Suisse prices $935,000 contingent coupon autocallables on three stocks
|
11/9/2017 | SP | Credit Suisse plans 19.25% contingent coupon autocalls tied to stocks
|
11/9/2017 | SP | Credit Suisse plans 20.85% contingent coupon autocalls tied to stocks
|
9/19/2017 | SP | New Issue: Barclays prices $2 million phoenix autocallables linked to three stocks
|
9/19/2017 | SP | New Issue: Barclays sells $1.65 million phoenix autocallables tied to three stocks
|
11/3/2016 | SP | New Issue: JPMorgan prices $6.6 million return notes linked to basket of 50 stocks
|
10/26/2016 | SP | JPMorgan plans one-year return notes linked to basket of 50 stocks
|
10/17/2016 | BK | Vertex Pharmaceuticals closes $500 million five-year revolver
|
9/16/2016 | SP | New Issue: HSBC prices $3 million of AMPS linked to basket of 20 common stocks
|
9/8/2016 | SP | HSBC plans 15-month AMPS with cap linked to basket of 20 stocks
|
3/7/2016 | SP | New Issue: Bank of America prices $2.2 million enhanced return notes on 10 stocks
|
2/29/2016 | SP | Bank of America to price enhanced return notes linked to 10 stocks
|
1/21/2016 | SP | New Issue: Credit Suisse sells $162,000 autocallable reverse convertibles on Vertex
|
1/4/2016 | SP | Credit Suisse plans autocallable reverse convertibles linked to Vertex
|
10/27/2015 | BK | Vertex Pharmaceuticals amends credit facility repayment schedule
|
7/23/2015 | SP | New Issue: HSBC prices $1.41 million 9% one-year autocallable yield notes linked to Vertex
|
7/13/2015 | SP | HSBC plans 9% one-year autocallable yield notes linked to Vertex
|
6/11/2015 | SP | New Issue: JPMorgan prices $3.26 million capped return enhanced notes on S&P 500
|
5/29/2015 | SP | New Issue: Barclays prices $5.25 million 7.1% airbag autocallables on Vertex Pharmaceuticals
|
5/20/2015 | SP | Barclays plans 6%-8% airbag autocallables on Vertex Pharmaceuticals
|
4/14/2015 | SP | New Issue: RBC prices $6.19 million airbag phoenix autocallables linked to Vertex
|
4/7/2015 | SP | RBC to price 9.75%-11.75% airbag phoenix autocallables tied to Vertex
|
4/6/2015 | SP | New Issue: Credit Suisse prices $746,000 10.5% autocallable reverse convertibles linked to Vertex
|
3/16/2015 | SP | Credit Suisse plans 10%-12% autocallable reverse convertibles on Vertex
|
2/27/2015 | SP | New Issue: RBC prices $4.36 million 9.6% airbag autocallables linked to Vertex
|
2/23/2015 | SP | RBC to price 7.8%-9.8% airbag phoenix autocallables linked to Vertex
|
1/30/2015 | SP | New Issue: UBS prices $250,000 trigger phoenix autocallable optimization securities linked to Vertex Pharmaceuticals
|
1/29/2015 | SP | New Issue: UBS prices $225,000 trigger phoenix autocallable optimization securities linked to Vertex Pharmaceuticals
|
12/1/2014 | SP | New Issue: HSBC prices $4.18 million 9% airbag autocallable yield notes on Vertex Pharmaceuticals
|
11/24/2014 | SP | New Issue: RBC prices $25,000 8.75% reverse convertibles linked to Vertex Pharmaceuticals
|
11/20/2014 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to Vertex Pharmaceuticals
|
11/20/2014 | SP | HSBC plans 7.4%-9.4% airbag autocallable yield notes linked to Vertex
|
11/18/2014 | SP | New Issue: UBS prices $174,000 trigger phoenix autocallable optimization securities linked to Vertex Pharmaceuticals
|
11/12/2014 | SP | New Issue: JPMorgan prices $173,000 contingent absolute return autocallables on Vertex
|
11/7/2014 | SP | RBC to price 8.75% reverse convertibles linked to Vertex Pharmaceuticals
|
11/5/2014 | SP | JPMorgan plans contingent absolute return autocallables tied to Vertex
|
10/30/2014 | SP | New Issue: RBC prices $159,000 9.7% reverse convertibles linked to Vertex Pharmaceuticals
|
10/21/2014 | SP | New Issue: RBC prices $1.2 million 7.5% airbag autocallable notes linked to Vertex
|
10/14/2014 | SP | RBC to price 6%-7.2% airbag autocallables linked to Vertex
|
10/14/2014 | SP | RBC to price 8.3% reverse convertibles linked to Vertex Pharmaceuticals
|
10/9/2014 | SP | New Issue: UBS prices $335,000 contingent absolute return autocallable optimization securities linked to Vertex Pharmaceuticals
|
9/30/2014 | SP | New Issue: RBC prices $191,000 9% reverse convertibles linked to Vertex Pharmaceuticals
|
9/22/2014 | SP | RBC to price 9% reverse convertibles linked to Vertex Pharmaceuticals
|
9/17/2014 | SP | New Issue: RBC prices $32,000 10.25% reverse convertibles linked to Vertex Pharmaceuticals
|
9/12/2014 | SP | New Issue: UBS prices $427,000 trigger phoenix autocallable optimization securities linked to Vertex Pharmaceuticals
|
9/11/2014 | SP | New Issue: UBS prices $1 million trigger phoenix autocallable optimization securities linked to Vertex Pharmaceuticals
|
9/11/2014 | SP | RBC to price 10.25% reverse convertibles linked to Vertex Pharmaceuticals
|
9/5/2014 | SP | New Issue: UBS prices $937,000 trigger phoenix autocallable optimization securities linked to Vertex Pharmaceuticals
|
9/5/2014 | SP | New Issue: UBS prices $942,000 trigger phoenix autocallable optimization securities linked to Vertex Pharmaceuticals
|
9/3/2014 | SP | New Issue: UBS prices $305,000 trigger phoenix autocallable optimization securities linked to Vertex Pharmaceuticals
|
8/27/2014 | SP | New Issue: UBS prices $6.13 million 8.88% airbag autocallables linked to Vertex
|
8/21/2014 | SP | RBC plans to price 10.8% reverse convertibles linked to Vertex
|
8/20/2014 | SP | New Issue: RBC prices $317,000 11.25% reverse convertibles linked to Vertex
|
8/20/2014 | SP | New Issue: UBS prices $1 million trigger autocallable optimization securities linked to Vertex Pharmaceuticals
|
8/20/2014 | SP | UBS plans to price 7.8%-9.8% airbag autocallables linked to Vertex
|
8/14/2014 | SP | New Issue: UBS prices $189,000 trigger phoenix autocallable optimization securities linked to Vertex Pharmaceuticals
|
8/13/2014 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to Vertex Pharmaceuticals
|
8/8/2014 | SP | RBC to price 11.25% reverse convertibles linked to Vertex
|
8/8/2014 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to Vertex Pharmaceuticals
|
8/4/2014 | SP | New Issue: UBS prices $150,000 airbag yield optimization notes linked to Vertex Pharmaceuticals
|
7/30/2014 | SP | New Issue: UBS prices $120,000 trigger phoenix autocallable optimization securities linked to Vertex Pharmaceuticals
|
7/24/2014 | SP | New Issue: UBS prices $114,924 7.46% trigger yield optimization notes linked to Vertex Pharmaceuticals
|
7/17/2014 | SP | New Issue: RBC prices $545,000 12.2% reverse convertibles linked to Vertex Pharmaceuticals
|
7/9/2014 | BK | Vertex Pharmaceuticals gets $300 million term loan at 7.2% initial rate
|
7/8/2014 | SP | New Issue: UBS prices $106,000 trigger phoenix autocallable optimization securities linked to Vertex Pharmaceuticals
|
7/7/2014 | SP | RBC to price 11.5% reverse convertibles linked to Vertex Pharmaceuticals
|
6/23/2014 | SP | New Issue: UBS prices $126,958 8.89% trigger yield optimization notes linked to Vertex Pharmaceuticals
|
6/19/2014 | SP | New Issue: UBS prices $100,000 airbag yield optimization notes linked to Vertex Pharmaceuticals
|
5/27/2014 | SP | New Issue: UBS prices $100,000 airbag yield optimization notes linked to Vertex Pharmaceuticals
|
5/8/2014 | SP | New Issue: UBS prices $999,937 15.8% trigger yield optimization notes linked to Vertex Pharmaceuticals
|
4/17/2014 | SP | New Issue: UBS prices $175,000 airbag yield optimization notes linked to Vertex Pharmaceuticals
|
4/11/2014 | SP | New Issue: UBS prices $200,000 airbag yield optimization notes linked to Vertex Pharmaceuticals
|
4/11/2014 | SP | New Issue: UBS prices $391,000 airbag yield optimization notes linked to Vertex Pharmaceuticals
|
3/19/2014 | SP | New Issue: UBS prices $149,998 19.48% trigger yield optimization notes linked to Vertex Pharmaceuticals
|
3/6/2014 | SP | New Issue: UBS prices $100,000 airbag yield optimization notes linked to Vertex Pharmaceuticals
|
3/4/2014 | SP | New Issue: UBS prices $100,000 airbag yield optimization notes linked to Vertex Pharmaceuticals
|
2/28/2014 | SP | New Issue: RBC prices $120,000 13.7% reverse convertibles linked to Vertex Pharmaceuticals
|
2/25/2014 | SP | New Issue: JPMorgan prices $19.44 million 11% airbag autocallables linked to Vertex
|
2/25/2014 | SP | New Issue: UBS prices $239,000 airbag yield optimization notes linked to Vertex Pharmaceuticals
|
2/20/2014 | SP | RBC to price 13% reverse convertibles linked to Vertex Pharmaceuticals
|
2/19/2014 | SP | New Issue: RBC prices $122,000 12.5% reverse convertibles linked to Vertex Pharmaceuticals
|
2/19/2014 | SP | JPMorgan to price 9.25%-11.25% airbag autocallables tied to Vertex
|
2/7/2014 | SP | New Issue: UBS prices $107,000 airbag yield optimization notes linked to Vertex Pharmaceuticals
|
2/7/2014 | SP | New Issue: UBS prices $110,000 airbag yield optimization notes linked to Vertex Pharmaceuticals
|
2/4/2014 | SP | RBC to price 12.5% reverse convertibles linked to Vertex Pharmaceuticals
|
1/27/2014 | SP | New Issue: UBS prices $217,000 trigger phoenix autocallable optimization securities linked to Vertex Pharmaceuticals
|
1/23/2014 | SP | New Issue: UBS prices $112,040 trigger phoenix autocallable optimization securities linked to Vertex Pharmaceuticals
|
1/22/2014 | SP | New Issue: UBS prices $730,000 trigger phoenix autocallable optimization securities linked to Vertex Pharmaceuticals
|
1/17/2014 | SP | New Issue: UBS prices $99,985 11.23% trigger yield optimization notes linked to Vertex Pharmaceuticals
|
1/15/2014 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to Vertex Pharmaceuticals
|
1/15/2014 | SP | New Issue: UBS prices $130,710 trigger phoenix autocallable optimization securities linked to Vertex Pharmaceuticals
|
1/14/2014 | SP | New Issue: UBS prices $210,000 airbag yield optimization notes linked to Vertex Pharmaceuticals
|
1/14/2014 | SP | New Issue: UBS prices $150,000 airbag yield optimization notes linked to Vertex Pharmaceuticals
|
1/10/2014 | SP | New Issue: UBS prices $183,000 airbag yield optimization notes linked to Vertex Pharmaceuticals
|
1/9/2014 | SP | New Issue: UBS prices $265,000 airbag yield optimization notes linked to Vertex Pharmaceuticals
|
12/31/2013 | CV | Outlook 2014: U.S. secondary market poised for continued strength, but investors eye Fed taper
|
12/17/2013 | SP | New Issue: UBS prices $725,000 airbag yield optimization notes linked to Vertex Pharmaceuticals
|
12/10/2013 | SP | New Issue: UBS prices $99,941 10.91% trigger yield optimization notes linked to Vertex Pharmaceuticals
|
12/9/2013 | SP | New Issue: UBS prices $127,000 trigger phoenix autocallable optimization securities linked to Vertex Pharmaceuticals
|
12/5/2013 | SP | New Issue: UBS prices $529,473 11.18% trigger yield optimization notes linked to Vertex Pharmaceuticals
|
12/4/2013 | SP | New Issue: UBS prices $274,841 11.27% trigger yield optimization notes linked to Vertex Pharmaceuticals
|
12/3/2013 | SP | New Issue: UBS prices $105,000 trigger phoenix autocallable optimization securities linked to Vertex Pharmaceuticals
|
12/3/2013 | SP | New Issue: UBS prices $124,900 10.79% trigger yield optimization notes linked to Vertex Pharmaceuticals
|
11/19/2013 | SP | New Issue: UBS prices $110,000 airbag yield optimization notes linked to Vertex Pharmaceuticals
|
11/15/2013 | SP | New Issue: UBS prices $358,900 trigger phoenix autocallable optimization securities linked to Vertex Pharmaceuticals
|
11/12/2013 | SP | New Issue: Deutsche prices $4.94 million 8.8% airbag autocallable yield notes on Vertex Pharmaceuticals
|
11/6/2013 | SP | Deutsche plans 6.8%-8.8% airbag autocallables on Vertex Pharmaceuticals
|
10/1/2013 | SP | New Issue: UBS prices $104,000 trigger phoenix autocallable optimization securities linked to Vertex Pharmaceuticals
|
8/27/2013 | SP | New Issue: RBC prices $1.81 million airbag yield optimization notes linked to Vertex Pharmaceuticals
|
8/21/2013 | SP | RBC plans 6.5%-8.5% airbag yield optimization notes linked to Vertex
|
5/17/2013 | CVLM | Vertex Pharmaceuticals calls $400 million 3.35% convertibles due 2015
|
4/22/2013 | CV | Market Commentary: Integra LifeSciences flat to lower; Vertex quiet after surge; Intel, Microsoft in trade
|
4/19/2013 | CV | Market Commentary: Vertex higher on drug study data; Cobalt improves dollar-neutral; Intelsat extends gains
|
2/26/2013 | SP | New Issue: Barclays prices $7.32 million 12.55% airbag notes linked to Vertex Pharmaceuticals
|
2/21/2013 | SP | Barclays plans 9%-11% airbag yield notes tied to Vertex Pharmaceuticals
|
12/20/2012 | SP | New Issue: JPMorgan prices $715,380 contingent absolute return autocallables on Vertex
|
12/12/2012 | SP | JPMorgan plans contingent absolute return autocallables on Vertex
|
12/4/2012 | CV | Market Commentary: Volcano deal upsized, trades up in gray market; existing Volcano quiet; Seacor deal on tap
|
11/13/2012 | CV | Market Commentary: Gilead trades mixed on data; Vertex in line; CEDC sinks in light trade; GT Advanced down
|
11/2/2012 | CV | Market Commentary: Dendreon higher after wider loss; Vertex up on hedge after earnings miss; Chesapeake quiet
|
10/23/2012 | SP | New Issue: Deutsche Bank prices $1.59 million airbag yield optimization notes linked to Vertex Pharmaceuticals
|
10/17/2012 | SP | Deutsche Bank plans 7%-9.5% airbag notes on Vertex Pharmaceuticals
|
8/24/2012 | CV | Market Commentary: Convertibles mostly quiet; Gilead comes in slightly; Vertex static; Endo moves up a little
|
8/2/2012 | CV | Market Commentary: Knight swings wildly, extends slide after 'glitch'; Gilead adds on rival's suspended trial
|
7/9/2012 | SP | New Issue: RBC prices $934,000 10.85% airbag notes linked to Vertex
|
7/3/2012 | CV | Market Commentary: Convertibles quiet ahead of holiday; Lincare, Theravance extend gains; U.S. Steel better
|
7/2/2012 | SP | RBC plans 8.5%-11% airbag yield optimization notes linked to Vertex
|
5/29/2012 | CV | Market Commentary: Vertex pops on hedge after drug data benefits curbed; coal names eyed; Vishay to price
|
5/8/2012 | CV | Market Commentary: Thompson Creek slides; Annaly on tap; Dendreon drops outright, on hedge; Salix seen flat
|
5/7/2012 | CV | Market Commentary: Thompson Creek's $200 million unit deal looks cheap; Vertex adds dollar neutral; GM up
|
2/29/2012 | SP | New Issue: RBC prices $3.38 million 12.94% airbag notes linked to Vertex
|
2/23/2012 | SP | RBC plans 10%-13% airbag yield optimization notes linked to Vertex
|
1/9/2012 | CV | Market Commentary: Convertibles revert to 'quiet'; Alcoa firm to better ahead of earnings; Amgen steady
|
1/6/2012 | CV | Market Commentary: Convertibles start year strong; Regeneron jumps to 104; Dendreon gains; RF Micro drops
|
10/26/2011 | HYLM | Vertex Pharmaceuticals to redeem $105 million of notes at month-end
|
9/29/2011 | SP | New Issue: Bank of Montreal prices $343,000 14% reverse exchangeables on Vertex
|
9/21/2011 | SP | Bank of Montreal plans 14% reverse exchangeables linked to Vertex
|
8/9/2011 | SP | New Issue: RBC prices $3.02 million 12.75% trigger yield notes linked to Vertex Pharmaceuticals
|
8/5/2011 | CV | Market Commentary: Convertibles see limited bargain hunting; Vertex up on short covering; high grade firms
|
8/2/2011 | SP | RBC plans 9.5%-12% trigger yield optimization notes linked to Vertex
|
7/7/2011 | SP | New Issue: JPMorgan prices $5.29 million 16% reverse convertibles linked to Vertex Pharmaceuticals
|
6/10/2011 | CV | Market Commentary: Molycorp jumps on debut, but Integra drops; new Brookside extends losses; Vertex expands
|
6/9/2011 | CV | Market Commentary: Brookdale slips on debut; Forestar scraps deal; Molycorp looks cheap after revised talk
|
5/17/2011 | SP | New Issue: Bank of Montreal prices $5,000 12% reverse exchangeables on Vertex
|
5/2/2011 | SP | Bank of Montreal plans 12% reverse exchangeables linked to Vertex
|
4/19/2011 | SP | New Issue: Bank of Montreal prices $742,000 19.15% reverse exchangeables on Vertex
|
3/30/2011 | SP | Bank of Montreal plans 19.15% reverse exchangeables linked to Vertex
|
3/29/2011 | CV | Market Commentary: Goodyear slips; InterDigital up in gray; Mentor on tap; A123 short on borrow; Vertex rises
|
2/16/2011 | HYLM | Vertex to redeem $50 million of secured notes due 2012 at par
|
1/13/2011 | BK | Vertex Pharmaceuticals adds $100 million undrawn revolver via BofA
|
12/3/2010 | CV | Market Commentary: Clearwire slumps on debut as hedge players steer clear; Vertex below par; Cameron rises
|
10/28/2010 | CV | Market Commentary: Energy XXI bid higher in gray market; Flagstar's $270 million preferreds quiet on debut
|
9/24/2010 | CV | Market Commentary: Carnival crushed on call; AMD mixed, quiet; convertibles generally better with equity rally
|
9/24/2010 | CV | Vertex greenshoe fully exercised, lifts convertibles to $400 million
|
9/23/2010 | CV | New Issue: Vertex Pharmaceuticals prices $375 million of five-year convertibles to yield 3.35%, up 35%
|
9/23/2010 | CV | Market Commentary: Vertex Pharma adds on active debut; Avis, Hertz slip; Rite Aid down, but CBIZ adds to debut
|
9/22/2010 | CV | Vertex Pharmaceuticals to price $375 million of five-year convertibles to yield 3%-3.5%, up 35%
|
9/22/2010 | CV | Market Commentary: CBIZ higher on quiet debut; AMR weaker on disappointing guidance; Vertex to price pre-open
|
5/27/2010 | SP | New Issue: Barclays prices $0.25 million 15% reverse convertibles linked to Vertex Pharmaceuticals
|
5/11/2010 | SP | Barclays to price 15% reverse convertibles linked to Vertex Pharmaceuticals
|
4/29/2010 | SP | New Issue: Barclays prices $1 million 11.75% reverse convertibles linked to Vertex Pharmaceuticals
|
4/12/2010 | SP | Barclays to price 11.75% reverse convertibles linked to Vertex Pharmaceuticals
|
3/31/2010 | SP | New Issue: Barclays prices $4 million 10.5% reverse convertibles linked to Vertex Pharmaceuticals
|
3/9/2010 | SP | Barclays to price 10.5% reverse convertibles linked to Vertex Pharmaceuticals
|
3/2/2010 | SP | New Issue: Barclays sells $10 million more 10.25% reverse convertibles linked to Vertex Pharmaceuticals
|
2/25/2010 | SP | New Issue: Barclays prices $2.5 million 10.25% reverse convertibles linked to Vertex Pharmaceuticals
|
2/19/2010 | CVHY | Vertex Pharmaceuticals files automatic shelf covering stock and debt
|
2/16/2010 | CV | Vertex calls $32.1 million 4.75% convertibles for redemption at 102.85
|
2/8/2010 | SP | Barclays to price 10.25% reverse convertibles linked to Vertex Pharmaceuticals
|
2/1/2010 | SP | New Issue: Wells Fargo sells $2.38 million 15% enhanced yield notes on Vertex for Eksportfinans
|
1/29/2010 | SP | New Issue: Barclays prices $2 million 12% reverse convertibles linked to Vertex Pharmaceuticals
|
1/20/2010 | SP | Wells Fargo to price 12%-13% enhanced yield securities linked to Vertex for Eksportfinans
|
1/8/2010 | SP | Barclays to price 12% reverse convertibles linked to Vertex Pharmaceuticals
|
11/16/2009 | CV | Vertex holders to swap $111.9 million convertibles due 2013 for stock
|
11/10/2009 | CV | Vertex to issue stock in exchange for $109 million 4.75% convertibles
|
10/6/2009 | HYPV | New Issue: Vertex Pharmaceuticals generates $122.2 million from sale of notes due 2012
|
9/30/2009 | PV | New issue: Vertex to generate $120 million from secured notes
|
6/11/2009 | CV | Vertex to issue shares in exchange for $143.5 million convertibles
|
6/8/2009 | CV | Vertex to issue shares in exchange for $143.5 million of convertibles
|
2/14/2008 | CV | Vertex greenshoe exercised, lifts 4.75% convertibles to $287.5 million
|
2/13/2008 | CV | Market Commentary: Vertex Pharmaceuticals shines; Nortel up on venture talk; AMD up on EU's Intel raid; SLM upgraded
|
2/13/2008 | CV | New Issue: Vertex prices $250 million 4.75% convertible senior notes due 2103, up 35%
|
2/12/2008 | CV | Market Commentary: Flotek, GMX Resources price deals cheap; Vertex coming next; Financials mixed on mortgage deal
|
2/12/2008 | CV | Vertex prices $250 million convertibles to yield 4.75%, up 35%
|
2/11/2008 | CV | Vertex Pharmaceuticals launches $250 million convertibles due 2013; talked at 4.75%-5.25%, up 27.5%-32.5%
|
2/11/2008 | CV | Market Commentary: Yahoo! up after rejecting Microsoft; Flotek, Vertex Pharma bringing deals; GM, Schering-Plough earnings ahead
|
11/5/2007 | SP | Barclays to price 18% reverse convertibles linked to Vertex
|
10/24/2007 | SP | New Issue: RBC prices $1 million of 17.3% reverse convertibles linked to Vertex
|
7/27/2007 | SP | New Issue: ABN Amro prices $500,000 20.3% reverse convertibles linked to Vertex
|
7/26/2007 | SP | New Issue: Barclays prices $1.5 million 19% reverse convertibles linked to Vertex Pharmaceuticals
|
7/10/2007 | SP | Barclays to price 19% reverse convertibles linked to Vertex Pharmaceuticals
|
7/6/2007 | SP | ABN Amro plans 20.30% knock-in notes linked to Vertex Pharmaceuticals
|
7/3/2007 | SP | ABN Amro plans 20.3% reverse exchangeable securities linked to Vertex
|
6/29/2007 | SP | New Issue: Wachovia prices $9.717 million 14.25% enhanced yield securities linked to Vertex
|
6/5/2007 | SP | Rabo to price 12.7% knock-in reverse convertibles linked to Vertex Pharmaceuticals via LaSalle
|
6/1/2007 | SP | Wachovia to price enhanced yield securities linked to Vertex
|
5/22/2007 | SP | Rabo to price 15.5% knock-in reverse convertibles linked to Vertex Pharmaceuticals via LaSalle
|
5/3/2007 | SP | New Issue: Natixis prices $1.15 million 13.75% reverse convertibles linked to Vertex for Eksportfinans
|
5/1/2007 | SP | Rabo to price 15.5% reverse convertibles linked to Vertex
|
4/27/2007 | SP | New Issue: HSBC sells $565,000 29% reverse convertibles linked to Vertex
|
4/13/2007 | SP | Market Commentary: Lehman to price notes linked to Israeli shekel; Barclays plans S&P 500-linked notes
|
4/5/2007 | SP | HSBC to issue 29% reverse convertibles linked to Vertex Pharmaceuticals
|
3/27/2007 | SP | New Issue: HSBC USA prices $3.002 million 29.25% notes linked to Vertex
|
3/6/2007 | SP | HSBC to issue 29.25% reverse convertibles linked to Vertex
|
3/5/2007 | CV | Vertex Pharmaceuticals 5.75% convertible holders convert ahead of redemption
|
2/2/2007 | CV | Vertex Pharmaceuticals calls 5.75% convertibles due 2011
|
10/27/2006 | BT | Vertex reiterated at market perform by JMP
|
10/27/2006 | BT | Vertex maintained buy by Merrill
|
10/27/2006 | BT | Market Commentary: Genzyme slides on deal buzz; Cadence, Achillion up; Aspreva falls; Vertex gains 18%; Critical off on PIPE
|
10/26/2006 | BT | Vertex says well positioned to pursue development with $752.3 million in cash
|
9/28/2006 | BT | Vertex upgraded to buy by Merrill
|
9/21/2006 | BT | Vertex expects to achieve first milestones in Prove trials in Q4
|
9/15/2006 | BT | Market Commentary: Vertex slips but deal a hit; Barrier, Auxilium rise on PIPEs deals; ImClone, Encysive, Arena higher
|
9/14/2006 | BT | New Issue: Vertex prices upsized 9.1 million shares at $33.00 for total of $300 million
|
9/13/2006 | BT | Market Commentary: Vasogen zooms 24% on Celacade data; Cardiome off 11%; Oscient falls 11%, but fans buy on decline
|
9/12/2006 | BT | Market Commentary: Oscient may bounce on expected FDA rejection; New River rises 6%; Adolor flat, Progenics lower
|
9/11/2006 | BT | Market Commentary: Genentech falls on Avastin delay; Vertex pitches $300 million deal; OSI off 2%; Genitope loses 5%
|
9/11/2006 | BT | Vertex Pharmaceuticals registers stock in automatic shelf filing
|
9/11/2006 | BT | Vertex launches follow-on offering of 8 million shares via Merrill Lynch
|
8/17/2006 | BT | Vertex, Glaxo's Lexiva provided comparable efficacy to Kaletra in study
|
8/9/2006 | BT | Vertex sells Altus stock for $11.7 million
|
8/3/2006 | BTCV | Vertex Pharmaceuticals to issue 4.1 million shares for $58.3 million 5.75% convertibles
|
7/27/2006 | BT | JMP reiterates Vertex at market perform
|
7/27/2006 | BT | Vertex rated at neutral by Merrill
|
7/26/2006 | BT | Vertex GAAP net loss increases to $77.7 million
|
7/25/2006 | BT | Vertex given neutral rating by Merrill
|
7/11/2006 | BT | Market Commentary: Connetics stock regains 3%; Anadys adds 8% on new exec, moves Idenix, Vertex up, too; Xoma rises 5%
|
6/30/2006 | BT | Vertex forms collaboration with Johnson & Johnson companies to promote VX-950 for hepatitis C
|
6/30/2006 | BT | Vertex kept at market perform by JMP
|
6/30/2006 | BT | Merrill puts Vertex at neutral
|
6/30/2006 | BT | Market Commentary: Vertex soars 15% on J&J deal; Cephalon climbs over 10% on Fentora nod; Barr off slightly
|
6/26/2006 | BT | Vertex extends research program with Merck
|
6/22/2006 | BT | Vertex says 900,000 hepatitis C patients in the United States are awaiting better treatment
|
6/15/2006 | BT | Vertex plans to enroll 1,000 hepatitis C patients in VX-950 trials by 2007
|
6/6/2006 | BT | Market Commentary: Xenoport deal emerges; Human Genome up 4%; Anadys, Idenix drop on HGSI news; Onyx up
|
5/23/2006 | BT | Vertex begins Prove 1, to begin Prove 2 studies of VX-950 for treatment of hepatitis C virus
|
5/22/2006 | BT | Vertex: Studies show VX-950 reduces hepatitis C virus to undetectable levels
|
5/17/2006 | BT | Vertex starts cystic fibrosis study
|
5/17/2006 | BT | Vertex ready to launch full phase 2 study of VX-950
|
5/17/2006 | BT | Market Commentary: Vivus up 15%; Hana off 10% on PIPE deal; Restore gains on debut; NxStage drops on follow-on deal
|
5/1/2006 | BT | Vertex: Data shows VX-950 with pegylated interferon achieves dramatic drop in hepatitis C viral levels
|
4/26/2006 | BT | Merrill rates Vertex at neutral
|
4/26/2006 | BT | Vertex at market perform by JMP
|
4/26/2006 | BT | Vertex to highlight anti-HCV activity of VX-950 at annual meeting in Vienna
|
4/25/2006 | BT | Vertex first-quarter revenues up more than $11 million
|
4/21/2006 | BT | Vertex neutral rating unchanged by Merrill
|
4/5/2006 | BT | Vertex: Phase 2 program for VX-680 to treat colorectal cancer triggers $10 million milestone
|
4/4/2006 | BT | Market Commentary: Valeant up on restructuring; Nabi gains; Avanir rises on drug filing; Enzon higher; ViroPharma eyed
|
3/23/2006 | BT | Vertex, Cystic Fibrosis Foundation Therapeutics to develop oral drug VX-770
|
3/9/2006 | BT | Vertex neutral rating unchanged by Merrill
|
3/9/2006 | BT | Market Commentary: NPS Pharma weak ahead of FDA; Dyax plunges; Insmed up slightly; Vertex dives; Elan off, Biogen up
|
3/8/2006 | BT | Vertex says VX-702 for rheumatoid arthritis met primary objectives in phase 2 study
|
2/14/2006 | BT | Vertex continues VX-950's broad phase 2 program in 2006; New Drug Application seen in 2008
|
2/8/2006 | BT | Merrill keeps Vertex at neutral
|
2/8/2006 | BT | Bear Stearns downgrades Vertex to peer perform
|
2/7/2006 | BT | Vertex keeps neutral rating from Merrill
|
2/7/2006 | BT | Market Commentary: Alexion hits new high; Vertex up on data, earnings; Genitope lifted after deal; Oscient up on new pact
|
2/7/2006 | BT | Vertex VX-950 cuts hepatitis C in initial response to dosing
|
2/1/2006 | BT | Merrill keeps Vertex at neutral
|
2/1/2006 | BT | Market Commentary: Vertex gains; SGX debuts higher; Angiotech up; Alnylam off; DUSA dives; Endo slides; Isis bounces
|
1/27/2006 | BT | Market Commentary: Arena up after follow-on; Altus interest grows; Nektar, Pfizer up; Glaxo gains on Gates' TB pledge; Teva prices
|
1/26/2006 | BT | Market Commentary: Altus rockets out of gate; Teva talk tightened; Alexion zooms; Amylin better; Cephalon gains; Nektar rises
|
1/25/2006 | BT | Market Commentary: Teva launches $2.75 billion bonds; NitroMed pockets $52.6 million; SGX Pharma sweetens IPO talk
|
1/12/2006 | BT | Vertex to get additional $22 million from partner in cystic fibrosis drug research
|
1/11/2006 | BT | Market Commentary: PDL, OSI Pharma, Biogen dive; Altus IPO launches, Vertex eases; Novogen shelves Glycotex IPO
|
1/9/2006 | BT | Merrill maintains Vertex at neutral
|
1/9/2006 | BT | Vertex: Phase 1b trial of VX-950 with pegylated interferon shows rapid drop in hepatitis C viral levels
|
12/16/2005 | BT | GlaxoSmithKline, Vertex's brecanavir suppresses HIV levels, study says
|
12/13/2005 | BT | Vertex could receive up to $405 million under VX-409 development deal with GlaxoSmithKline
|
12/8/2005 | BT | Vertex's hepatitis C drug VX-950 receives FDA fast track designation
|
12/7/2005 | BT | Vertex reaches milestone in collaboration with Merck to develop cancer treatments
|
12/5/2005 | BT | Vertex Pharmaceuticals launches phase 2 trial for oral hepatitis C inhibitor
|
11/28/2005 | BTCV | Vertex to exchange $95 million convertibles for stock
|
11/18/2005 | BT | Market Commentary: Onyx gains after 'well-priced' deal; Elan, Biogen rise; Protein Design Labs up; Cubist higher
|
11/15/2005 | BT | Vertex still neutral, Merrill Lynch says
|
11/11/2005 | BT | Vertex files application with FDA for phase II studies of VX-950 for hepatitis C treatment
|
11/9/2005 | BT | Leerink Swann rates Vertex outperform
|
10/27/2005 | BT | JMP reiterates Vertex at market perform
|
10/27/2005 | BT | Merrill keeps Vertex neutral
|
10/18/2005 | BT | Merrill Lynch maintains Vertex at neutral
|
10/5/2005 | BT | Market Commentary: Human Genome stock falls 29%, convertibles lose outright, up on swap; Vertex slides on profit taking
|
10/5/2005 | BT | Vertex's focus a positive for 2006, Merrill says
|
9/13/2005 | BT | Vertex reiterated by Merrill Lynch at neutral
|
9/9/2005 | BTCV | Vertex Pharmaceuticals to exchange $40.45 million convertibles due 2007 for 2.452 million shares
|
7/28/2005 | BT | Vertex maintained by Merrill at neutral
|
7/26/2005 | BT | Vertex reiterated by Merrill at neutral
|
6/17/2005 | BT | Market Commentary: Mylan Labs bond deal surfaces; Vertex up, Merck lags; Genentech rises; stem cell names watched
|
5/2/2005 | CV | Market Commentary: Corixa converts climb to par on takeover, other biotechs mixed; Calpine higher; Primus plunges
|
4/1/2005 | CV | Vertex Pharmaceuticals files $200 million shelf
|
9/13/2004 | CV | Vertex exchanges $79.3 million convertibles for new notes
|
2/10/2004 | CV | Vertex exchanges $153.5 million 5% convertibles
|
8/8/2002 | CV | Salomon halts shift to equity-sensitive issues in recommended convertibles portfolio
|
6/12/2002 | CV | Deutsche on biopharma: buy Inhale, Cell Therapeutics; hold Abgenix, Alexion; sell Vertex, ISIS
|
5/7/2002 | CV | Salomon adds three, removes three from recommended portfolio
|
4/10/2002 | CV | JPMorgan recommends 9 biotech convertibles for yield, capital appreciation, relative value
|
11/14/2001 | CV | Salomon says Vertex Pharmaceuticals risk worth the yield for tolerant investors
|